Remove

PTO/SB/08s (08-03)
Approved for use through 97/31/2006, 0NE 0851-0331
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number.

	Application Number		10597798	
INFORMATION DIGGLOSUPE	Filing Date		2006-08-08	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Rene		ne Graewe et al.	
(Not for submission under 37 CFR 1.99)	Art Unit			
	Examiner Name Unkn		nknown	
	Attorney Docket Numb	er	WAS 0796 PUSA	

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue E	Date	Name of Pate of cited Docu	entee or Applicant iment	Releva	Columns,Lines whe ant Passages or Rele s Appear	
	1									
If you wis	h to a	l dd additional U.S. Pate	nt citatio	n inform	ation pl	l lease click the	Add button.		Add	
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Pate of cited Docu	entee or Applicant iment	Releva	,Columns,Lines whe ant Passages or Rele s Appear	
	1									
If you wis	h to a	dd additional U.S. Publi		p		, , , , , , , , , , , , , , , , , , , ,		d button		
				FOREIG	SN PAT	ENT DOCUM	IENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code4	Publication Date	Name of Patentee Applicant of cited Document	or	Pages,Columns,Line where Relevant Passages or Releval Figures Appear	74
	1	2003-3140	JP			2003-01-08	Sekisul Chemical C Ltd.	So.		V
	2	62-43477	JP			1987-02-25	Nippon Synthetic C	chem.		Z
	3	2001-220563	JP			2001-08-14	Sekisui chemical C	io.		V

Application Number		10597798		
Filing Date		2006-08-08		
First Named Inventor Rene		Graewe et al.		
Art Unit				
Examiner Name	Unknown			
Attorney Docket Number		WAS 0796 PUSA		

If you wisl	h to a	d additional Foreign Patent Document citation information please click the Add button Add			
		NON-PATENT LITERATURE DOCUMENTS Remove			
Examiner Initials*	miner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, settlal, symposium, catalog, etc), date, pages(s), volume-issue number(s), put				
	1	Pathase Abstract corresonding to JP 2003-3140			
	2	Patbase Abstract corresponding to UP 62-43477			
	3	Patbase Abstract corresponding to JP 2001-220563			
If you wis	h to a	d additional non-patent literature document citation information please click the Add button Add			
		EXAMINER SIGNATURE			
Examiner	Signa	ure Date Considered			
		ial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a onformance and not considered. Include copy of this form with next communication to applicant.	1		

See Kind Code of USPTO Platent Documents at year, <u>USPTO,000</u> or MPEP 501.04. *Enter office half sever for document, by the two-later code (WPDO, Standard ST3.). **Explainese platest documents, the ancidation for beyond the great of the right of the Engener may provide the sent in unber for the plant document of year of the right of the great of the right of the Engener may provide a sent of the sen

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10597798		
Filing Date		2006-08-08		
First Named Inventor	Rene Graewe et al.			
Art Unit				
Examiner Name	Unknown			
Attorney Docket Number		WAS 0796 PUSA		

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.9	8 to make t	the appropria	priate selection(s):	
---------------	----------	---------	-------------	---------------	----------------------	--

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 197(eVI).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

- 7 See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- □ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/William G. Conger/	Date (YYYY-MM-DD)	2006-10-04
Name/Print	William G. Concer	Registration Number	31209

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to life (and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 122 and 37 CFR.

1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. 0. Bot 1450, Alexandria, V.S. 2213.1-450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2. 2213.1-450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicide is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually the principal purpose and for examines your submission, which may visually intermediate or of extended now about the principal purpose.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuint to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.